Minoxidil

Evidence Level: L5

Predicted Indications: 10

Minoxidil

Pharmacist Assessment Report

Minoxidil: From Hypertension and Hair Loss to Hypotrichosis Simplex of the Scalp

One-Sentence Summary

Minoxidil is a vasodilator, with relations to hypertensive disorder, hypertension and alopecia recorded in the knowledge graph. The TxGNN model predicts it may be useful for hypotrichosis simplex of the scalp, a rare hereditary hair disorder. Support currently consists of 0 registered clinical trials and 3 publications, all of them case reports in which minoxidil was combined with other treatments.

Quick Overview

Item	Content
Original Indication	Hypertensive disorder, hypertension and alopecia (relations recorded in the knowledge graph; the licence records compiled for this report contain no approved-indication text)
Predicted New Indication	Hypotrichosis simplex of the scalp
TxGNN Prediction Score	1.0000
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Number of Approvals	At least 20 single-ingredient licences (the list may be partial)
Recommended Decision	Hold

The data compiled for this report assigned L4 to this prediction. Because the 3 cited publications are case reports that all combine minoxidil with other treatments, and no study isolates minoxidil’s effect on this disease, I have placed it at L5 under the evidence-level ceiling rule.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data from DrugBank is not available. Based on the literature compiled for this report, minoxidil is converted to an active sulfate metabolite that opens ATP-sensitive potassium channels. In hair follicles it is thought to prolong the anagen (growth) phase and enlarge follicles. Its vasodilator action is also what lowers blood pressure when it is given orally at higher doses.

Hypotrichosis simplex of the scalp is a rare, inherited disorder (linked to variants such as CDSN) in which hair density and length are reduced. Minoxidil’s follicle-stimulating action therefore offers a plausible, though unproven, link. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

A key limitation is that all three publications describe minoxidil together with growth factors, botanical extracts or platelet-rich plasma. The contribution of minoxidil alone cannot be separated from these other treatments.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35761391	2022	Case report/series	Dermatologic Therapy	Hereditary hypotrichosis simplex of the scalp treated with oral minoxidil plus growth factors
39902296	2024	Case report	Frontiers in Genetics	8-year-old boy with CDSN-related hypotrichosis simplex treated with botanical extracts plus minoxidil
36651821	2023	Case report	Journal of Dermatological Treatment	14-year-old patient treated with platelet-rich plasma injections plus topical minoxidil 2%

India Market Information

The licence records compiled for this report contain no approved-indication text. The list below shows 5 of at least 20 valid single-ingredient licences, and the full list may be partial.

Authorization Number	Product Name	Dosage Form	Approved Indication
135535	Mintop Forte 2 Hair Restore Formula	Bottle of 60 ml solution	Not stated in the records
104773	Hairz 5 Solution	Bottle of 60 ml solution	Not stated in the records
126031	Lonit 10mg Tablet	Strip of 10 tablets	Not stated in the records
200268	Staha 5mg Tablet	Strip of 10 tablets	Not stated in the records
134106	Minogain 2.5mg Tablet	Bottle of 30 tablets	Not stated in the records

Both topical (solution, lotion) and oral tablet forms are licensed.

Safety Considerations

Package insert warnings and contraindications were not available. Please refer to the package insert for safety information. The following items come from other sources.

Relations recorded in the knowledge graph (not label text): The knowledge graph lists contraindication relations with, among others, heart disease, myocardial infarction, stroke and cerebrovascular disorders, pericardial effusion and cardiac tamponade, pheochromocytoma, orthostatic hypotension, kidney disease and scalp dermatosis.
Drug interactions: 275 interactions are recorded in total. Examples at moderate level include corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone), bupropion, morphine, opium, SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), dronabinol, nabilone and sapropterin.
Cardiovascular caution: Minoxidil given orally is associated with fluid retention, pericardial effusion and reflex tachycardia. This matters most for a rare disease affecting children, since the case reports include patients aged 8 and 14.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high and minoxidil is widely available in India. However, no registered trial exists, and the only evidence is three case reports in which minoxidil was always combined with other treatments. That is not enough to attribute benefit to minoxidil itself, so this remains a research question.

To proceed, the following is needed:

Package insert warnings and contraindications from the India licence holders
Mechanism-of-action data from DrugBank
Controlled or single-agent data on minoxidil for hereditary hypotrichosis simplex
A route and dose decision (topical versus oral), with a cardiovascular safety plan for any oral use in children
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.